Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents

Cannabis Dependence Clinical Trial

Official title:

Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01110434
• Other study ID #: R01DA026778
• Secondary ID: R01DA026778
• Status: Completed
• Phase: Phase 2
• Start date: December 2009
• Est. completion date: May 2012

Study information

• Verified date: August 2020
• Source: Brown University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cannabis use is a significant public health concern that disproportionately affect youth. Although promising psychosocial interventions are being developed, most youth do not benefit from these interventions alone. Given the clinical demand for effective treatments, the National Institute on Drug Abuse (NIDA) identified the critical need for data on the tolerability and potential efficacy of medications in adolescents. The purpose of this two-year study is to test if and how topiramate, a medication under intense study for treating several drugs of abuse, reduces cannabis use among teenagers. To this end, the investigators will randomize 56 nontreatment-seeking regular cannabis users (15 or 20 years old) to receive topiramate or placebo for 6 weeks. Youth will monitor their cannabis use for the 6-week period using handheld electronic diaries and complete assessments of reactivity to cannabis-related cues.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years to 20 Years

Eligibility

Inclusion Criteria:

• 15 to 20 years old (inclusive)

• Non-treatment seeking for cannabis abuse or dependence

• Able to read English, understand their rights as provided by the informed consent process, and be willing to sign an informed consent form to participant in the study

• If younger than 18 years old, informed consent from a parent or legal guardian is required

• Used cannabis at least 2 days per week during the past 30 days

Exclusion Criteria:

• Treatment seeking or a recent history of treatment for cannabis abuse or dependence

• Endorses a current commitment to stop using cannabis

• Clinically significant physical abnormalities as indicated by physical exam, hematological assessment, bilirubin concentration or urinalysis

• History of renal impairment, renal stones, seizures, or unstable hypertension

• Underweight (i.e., less than the 5th percentile) or overweight (equal to or greater than the 95th percentile), as determined by the Body Mass Index

• Positive urine toxicology screen for narcotics, amphetamines, or sedative hypnotics or self-reported drug use, other than cannabis, alcohol or nicotine, in the past 30 days

• Pregnant, nursing, or refusal to use reliable barrier method of birth control (e.g., condom), if female

• Took a psychotropic medication in the past 30 days

• Taking medications with a potential effect on cannabis use or a carbonic anhydrase inhibitor

• Suicidal

• A current DSM-IV-TR Axis I diagnosis other than attention- deficit/hyperactivity disorder or a disruptive behavior disorder

• A current substance use disorder other than a cannabis, alcohol, and nicotine use disorders

• Significant alcohol withdrawal symptoms

• Known sensitivity to topiramate

Related Conditions & MeSH terms

• Cannabis Abuse
• Cannabis Dependence
• Marijuana Abuse

Intervention

Drug:
• Topiramate
Topiramate (200 mg daily)
• Placebo
Placebo (daily)

Locations

Country	Name	City	State
United States	Brown University, Center for Alcohol and Addiction Studies	Providence	Rhode Island

Sponsors (2)

Lead Sponsor	Collaborator
Brown University	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cannabis Use	Frequency of Cannabis Use (Percent Use Days Per Week)	Weeks 1-6
Secondary	Quantity of Cannabis Use	Total Grams of Cannabis Use Per week	Weeks 1-6
Secondary	Amount of Cannabis Use Per Use Day	Average Grams of Cannabis Used Per Use Day	Weeks 1-6